## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Graham Nigel Maw, et al. :

APPLICATION NO.: Not Yet Assigned : Examiner:

FILING DATE: Herewith : Group Art Unit:

TITLE: Compounds for the Treatment of Female Sexual:

Dysfunction

Hon. Commissioner for Patents Washington, D.C. 20231

Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s). The references for this application can be found in the parent case U.S. Non-Provisional Application No. 09/708,392.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: October 15, 500 3 When L. Musser

Arlene K. Musser

Attorney for Applicant(s)

Reg. No. 37,895

Pfizer Inc.

Patent Department, MS 8260-1611

Eastern Point Road

Groton, Connecticut 06340

(860) 715-0871

EXPRESS MAIL NO. <u>EV 398</u>059902, U.S.

INFORMATION DISCLOSURE CITATION ATTY. DOCKET NO. PC10343D SERIAL I								NO.Not Ye	D.Not Yet Assigned					
							aham Nigel Maw, et al.							
FILING DATE Herewit									with GROUP					
	U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	` <u> </u>	DOCUMENT NUMBER			DATE	NAME	CLA	SS SUBCLA	ISS FILI	ING DATE PROPRIATE				
	US	4	6	6	6	9	0	3	5/19/87	Hamilton	51	4 229		
	US	5	5	7	1	ð	6	8	11/12/96	Stamler, et a	al. 51	4 562		
	us	5	9	8	1	5	2	7	11/9/99	Daugan, et a	al. 51	4 290		
	us	5	8	6	1	3	9		1/19/99	Niewohner, et	t al. 51	4 234.:	2	
	us	5	6	1	2	3	1	4	3/18/97	Stamler, et a	al. 51	4 13		
	us	6	0	4	3	2	5	2	3/28/00	Bombrun	51	4 292	$\perp$	
	us	6	2	9	4	5	5	0	9/25/01	Place, et al	l. 51	4 302	$\perp$	
	us	6	3	1	6	4	5	7	11/13/01	Garvey, et a	al. 51	4 263		
	us	6	3	0	6	8	4	1	10/23/01	Place, et al	l. 51	4 149		
						FORI	EIGN PAT	ENT DO	OCUMEN.	rs				
		•	DOX	CUMENT NU	JMBER				DATE	COUNTRY	CLA	SS SUBCLA		NSLATION
	Ţ				$\overline{}$		<del></del>		-				YES	S NO
1	EP	9	9	1	1	•	3	3	4/24/99	European	C0	7D 487/0	4	
	EP	0	7	7	1	7	9	9	7/5/97	European	C0	7D 473/0	0	
	EP	e	2	7	4	4	3	4	7/13/88	European	C0	7D 409/0	6	
	wo	€	1	0	7	6	4	2	4/4/91	Internationa	al A6	1K 37/0	2	
	wo	9	7	2	0	е	2	1	6/12/97	Internationa	al CO	7D 239/9	5	
	wo	8	7	3	5	9	8	0	10/2/97	Internationa	al C1:	2N 15/5	5	
	wo	•	7	3	9	7	6	8	10/30/97	Internationa	al A6	1K 33/2	3	
	wo	9	е	2	3	4	9	2	1/29/98	Internationa	al CO	7D 295/1	8	
	wo	<u> </u>	9	2	0	2	6	6	4/29/99	Internationa	al A6	1K 31/1	9	
	wo	9	9	2	7	5	6	2	5/6/99	Internationa	al A6	1K 31/55	7	
	wo	9	•	2	2	7	3	1	5/14/99	Internationa	al A6	1K 31/4	1	
	wo	c	0	1	5	6	3	3	3/23/00	Internationa	al Co	7D 471/0	4	
	wo	0	0	1	5	7	2	8	3/23/00	Internationa	al A6	1K 31/498	35	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
	Traish, A., Moreland, R. B., Huang, Y., et al., Mol. Cell Biol. Res. Comm., 2, 131-137 (1999).													

NFORMA	ATION DISCLOSURE CITATION	ATTY. DOCKET NO. PC10343D	SERIAL NO.Not Yet Assigned				
(Use	several sheets if necessary)	APPLICANT Graham Nigel Maw, et al.					
		FILING DATE Herewith	GROUP				
	Palle, Bredkjaer, Ottesen and Fahrer	nkrug 1990 Clinical and Experimental Pharmacolo	ogy and Physiology vol 17, 61-68.				
	Beavo JA and Reifsnyder DH, <i>Trends Pharmacol. Sci.</i> 11:150 (1990).						
	Wieshaar RE et al., J. Med. Chem.,	28, 537 (1985).					
	Giembycz MA, <i>Biochem. Pharm.</i> , <b>43</b> :2041 (1992).						
	Lowe JA and Cheng JB, <i>Drugs for the Future</i> , 17, 799-807 (1992).  Ashur-Fabian, O., Perl, O., Lilling, G., <i>et al.</i> ,. "SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neurona survival," <i>Peptides</i> , 20, 629-633 (1999).						
		Berman, J.R., Berman, L. & Goldstein, I., "Female sexual dysfunction: Incidence, pathophysiology, evaluation, and treatme options," <i>Urology</i> , <b>54</b> , 385-391 (1999).					
		Berman, J., Goldstein, I., Werbin, T. et al., "Double blind placebo controlled study with crossover to assess effect of slidenafii physiological parameters of the female sexual response," J. Urol., 161, 805 (1999)					
	Burnett, A, Calvin, D., Silver, R. et al. "Immunohistochemical description of nitric oxide synthase isoforms in human clitoris," J. 158, 75-78 (1997).						
	Diagnostic and statistical manual of mental disorders-IV, American Psychiatric Association: Washington, DC., pp. 493-518 (198						
		Fan, Y.P., Chakder, S & Ratton, S., "Inhibitory effect of zinc protoporphyrin IX on lower esophageal sphincter smooth must relaxation by vasoactive intestinal polypeptide and other receptor agonists," J. Pharmacol. Exp. Ther., 285, 468-474 (1998).					
	Foda, H.D., Sharaf, H.H. Absood, A. et al., "Pituitary adenylate cyclase-activating peptide (PACAP), a VIP-like peptide, prolonged airway smooth muscle relaxant activity," <i>Peptides</i> , 16, 1057-1061 (1995).						
	Frank, E., Anderson, C. & Rubinste (1978).	ein, D. "Frequency of sexual dysfunction in "norr	mai" couples," N. Engl. J. Med., 229, 111-				
	Goldstein, I. & Berman, J.R. "Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insuffici syndromes," <i>Int. J. Impot. Res.</i> , <b>10</b> , S84-S90 (1998).						
	Gu, Z.F., Jensen, R.T. & Maton, P agonists and neuropeptides,". Am J.	P.N. "A primary role for protein kinase A in smo Physiol., 263, G360-G364 (1992).	ooth muscle relaxation induced by adrene				
	Hauser-Kronberger, C., Cheung, A.,	Hacker, G. et al., "Peptidergic innervation of the h	numan clitoris," Peptides, 20, 539-543 (1999				
	Hoyle, C.H.V., Stones, R.W., Robsoneuropeptide containing nerves," J. A.	ovasculature of the human vagina by NOS					
	Ingenhoven, N. & Beck-Sickinger, A.G. "Flourescent labelled analogues of neuropeptide Y for the characterisation of expressing NPY receptor subtypes," J. Recept. Signal Transduct. Res., 17, 407-418 (1997).						
		. I. et al., "Predominant role for nitric oxide in t " Mol. Human Reprod., 4, 71-76 (1998).	he relaxation induced by vasoactive intest				
	Kaplan, S.A., Reis, R.B., Kohm, I.J Urology, <b>53</b> , 481-486 (1999).	. et al., "Safety and efficacy of sildenafil in post	tmenopausal women with sexual dysfunction				
	Kim, Y.C., Choi, H.K., Ahn, Y.S., et contractility," J. Androl., 15, 392-397	f al. "The effect of vasoactive intestinal polypepti (1994).	ide (VIP) on rabbit cavernosal smooth mu				
7/11	Laan, E. & Everaerd, W. "Physiologic	cal measures of vaginal vasocongestion,". Int. J. I	Impot. Res., 10, S107-S110 (1998).				
	Leiblum, S.R. "Definition and classific	cation of female sexual disorders," Int. J. Impoten	ce Res., 10, S104-S106 (1998).				

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. PC10343D	SERIAL NO.Not Yet Assigned					
(Use several sheets if necessary)	APPLICANT Graham Nigel Maw, et al.						
	FILING DATE Herewith GROUP						
Levin, R.J., "The physiology of sexual	function in women," Clin. Obstet. Gynecol., 7, 2	13-252 (1980).					
Levin, R.J., "VIP, vagina, clitoral and (1991).	Levin, R.J., "VIP, vagina, clitoral and preurethral glans.: An update on female genital arousal," Exp. Clin. Endocrinol., 98, 61-69 (1991).						
Levin, R.J., "The mechanisms of hum	an female sexual arousal," Ann. Rev. Sex Res., 3, 1-48 (1992).						
Levin, R.J., & Wagner, G.) "TRH and (1986	Levin, R.J., & Wagner, G.) "TRH and vaginal blood flow-effects in conscious women and anaesthetized sheep," J. Physiol., (1986						
Lundberg, J.M., Modin, A. & Malmstro Sci., 17, 301-304 (1996).	om, R.E. "Recent developments with neuropeptide Y receptor antagonists," <i>Trends. Pharmaci</i> en, H. et al., "Vasoactive intestinal oplypeptide (VIP) increases vaginal blood flow and inhib ur. J. Clin. Invest., 13, 321-324 (1983).						
Ottesen, B., Wagner, G & Fahrenk Pharmacological and Endocrinology pp 66-97. (1988).	Ottesen, B., Wagner, G & Fahrenkrug, J., Peptide innervation of the sexual organs. In: Handbook of Sexology, Vol. 6, T. Pharmacological and Endocrinology of Sexual Function, Sitsen, J.M.A. (eds), Amsterdam: Elsevier Science Publishers, chapter pp 66-97. (1988).  Ottensen, B. Pedersen, B., Nielsen, J. et al., "Vasoactive polypeptide (VIP) provokes vaginal lubrication in normal women," Peptide 8, 797-800 (1987).  Park, K., Goldstein, I., Andry, C., et al., "Vasculogenic female sexual dysfunction: The hemodynamic basis for vaginal engorgements insufficiency and clitoral erectile insufficiency," Int. J. Impotence Res., 9, 27-37 (1997).						
	Rosen, R. Taylor, J., Leiblum, S. et al., "Prevalence of sexual dysfunction in women: results of a survey of 329 women outpatient gynecological clinic," J. Sex Marital Ther., 19, 171-188 (1993).						
Schiavi, R.C. & Seagraves, R.T., "The	Schiavi, R.C. & Seagraves, R.T., "The biology of sexual function," Psychiat. Clin. North. Am., 18, 7-23 (1995).						
	Schoeffter, P. & Stoclet, J.C., "Effect of vasoactive intestinal polypeptide (VIP) on cyclic AMP level and relaxation in rat iso aorta," Eur. J. Pharmacol., 109, 275-279 (1985).  Serradeil-Le Gal, C., Valette, G., Rouby, P.E. et al., "SR 120819A, an orally-active and selective neuropeptide Y Y1 reantagonist," FEBS Letters, 3, 192-196 (1995).						
Sjoberg, I. "The vagina: Morphologica	al, functional and ecological aspects," Acta Obst. Gynecol. Scand., 71, 84-85 (1992).  ce and prevalence of sexual dysfunctions: a critical review of the empirical literature," Arch. Se						
Spector, I.P. & Carey, M.P. "Incidence Behav., 19, 389-408 (1990).							
Wagner, G. "Aspects of genital physic	ology and pathology," Sem. Neurol., 12, 87-97 (1	992).					
Werbin, T., Salimpour, P., Berman, stimulation," J. Urol., 161, 688 (1999).	L., et al., "Effect of sexual stimulation and age	e on genital blood flow in women and sext					
Wincze, J.P., Albert, a. & Bansal, S. " 22, 587-601 (1993).	Sexual arousal in diabetic females: Physiologica	al and self-report measures," Arch. Sex Beha					
	Wieland, H.A., Willim, K.D., Entzeroth, M. et al., "Subtype selectivity and antagonist profile of the nonpeptide Y1 receptor antag BIBP 3226," J Pharmacol Exp Ther., 275, 143-9 (1995).						
Ottesen, B. <u>American Journal of Obstemental Tract</u> , Volume 147, pages 20	etrics & Gynecology, "Vasoactive Intestinal Pept 8-224 (1983)	ide as a Neurotransmitter in the Female					
Clark, J.T., et al., <u>Endocrinology</u> , "Neupages 2435-2442 (1985)	uropeptide Y Stimulates Feeing But Inhibits Sexu	al Behavior in Rats", Volume 117, No. 6.,					
	<u>í Physiology,</u> "Neutral Endopeptridase Modulates e 271, No. 2, Part. 2, pages R393-R397 (1996)	s VIP-induced Vasodilalation In Hamster					
Erdos, E.G., et al., <u>Laboratory Investion</u> 737-747 (1985)	gation, "Neutral Metalloendopeptidase In Human	Male Genital Tract", Volume 52, No. 4, page					

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. PC10343D	SERIAL NO.Not Yet Assigned				
(Use several sheets if necessary)	APPLICANT Graham Nigel Maw, et al.					
	FILING DATE Herewith	GROUP				
United States Non-Provisional Patent Treatment of Female Sexual Dysfund	Application No. 09/708,344, filed November 8, 2000; Maw, et al., "Compounds for the tion", (Our Docket No. PC10931A)					
	United States Non-Provisional Patent Application No. 09/708,365, filed November 8, 2000; Maw, et al., "Compounds for the Treatment of Female Sexual Dysfunction", (Our Docket No. PC10932A)					
	United States Non-Provisional Patent Application No. 09/708,393, filed November 8, 2000; Maw, et al., "Compounds for the Treatment of Female Sexual Dysfunction", (Our Docket No. PC10930A)  Hedlund, et al., PNASu, "Erectile Dysfunction in Cyclin GMP-Dependent Kinase I-Deficient Mice", Volume 97, No. 5, pages 2349-2354 (2000)  U.S. 2002-0052370, filed April 02; Barber, et al., 514/237.5  U.S. 2002-0169101, filed November 2002; Gonzalez, et al., 514/1  US 2002/0028846  US2001/0051656					
U.S. 2002-0052370, filed April 02; Ba						
U.S. 2002-0169101, filed November 2						
US 2002/0028846						
US2001/0051656						
US2002/0019405						
EXAMINER	DATE CONSIDERED					

Conforms with FORM PTO-FB-A820 INFORMATION DISCLOSURE